895128-27-5

Upstream product

• 895128-26-4 methyl 2-(4-(benzyloxy)-3-methylphenyl)-2-ethylbutanoate 
• 338454-32-3 1-(benzyloxy)-4-bromo-2-methylbenzene 
• 100-39-0 benzyl bromide 
• 2362-12-1 4-Bromo-2-methylphenol 

Downstream Products

• 895128-28-6 2-(4-benzyloxy-3-methyl-phenyl)-2-ethyl-butyryl chloride 
• 1445853-78-0 2-(4-(benzyloxy)-3-methylphenyl)-2-ethylbutanamide 
• 1445853-79-1 ethyl 2-(2-(3-(4-(benzyloxy)-3-methylphenyl)pentan-3-yl)oxazol-4-yl)acetate 
• 1445853-82-6 ethyl 2-(2-(3-(4-hydroxy-3-methylphenyl)pentan-3-yl)oxazol-4-yl)acetate 
• 1445853-85-9 ethyl 2-(2-(3-(4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl)pentan-3-yl)oxazol-4-yl)acetate 
• 1445853-88-2 ethyl 2-(2-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)pentan-3-yl)oxazol-4-yl)acetate 
• 1445853-53-1 N-hydroxy-2-(2-(3-(4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl)pentan-3-yl)oxazol-4-yl)acetamide 

Relevant academic research and scientific papers

BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER

The present disclosure relates to novel bis-(aryl/heteroaryl)-methylene compounds of formula (I) having vitamin D receptor agonist and histone deacetylase (HDAC) inhibitory efficacy as well as to methods for reducing or inhibiting the proliferation of can

Vitamin D Receptor Modulators

The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R′, RP, RP3, LP1, LP2, ZP, RB, RB′, LXB and ZXB are as hereinafter defined, their preparation, pharmaceutical compositions, and methods of use.